Miras-Mirakian P, Claustrat F, Dechaud H, Pugeat M
Laboratoire de la Clinique endocrinologique, Hôpital de l'Antiquaille, Lyon.
J Gynecol Obstet Biol Reprod (Paris). 1992;21(4):419-23.
We have studied the response of prolactin (PRL) secretion to the test combining i.m. sulpiride in the dose 1 mg/kg followed by 200 micrograms i.v. of TRH, in 12 normal women and 37 patients with hyperprolactinaemia. The response was expressed as a percentage rise in plasma PRL concentration (delta %) 20 minutes after the administration of sulpiride or TRH. In the controls the response in PRL secretion to sulpiride worked out at between 639 and 2,760%. When there was a pituitary adenoma or supra-sellar lesion the PRL response to sulpiride was always less than 481%. On the other hand the PRL response with TRH after sulpiride was not significantly different as between the controls (less than 175%) and the patients (less than 91%). We conclude: 1) the combined sulpiride and TRH test is useless for assessing hyperprolactinaemia; 2) the sulpiride test on the other hand makes it possible to show that hyperprolactinaemia cannot be stimulated and to suspect the presence in this case of a prolactin producing adenoma or a supra-sellar tumour.
我们对12名正常女性和37名高催乳素血症患者进行了研究，采用肌肉注射1毫克/千克舒必利，随后静脉注射200微克促甲状腺激素释放激素（TRH）的联合试验，以观察催乳素（PRL）分泌的反应。反应以舒必利或TRH给药后20分钟血浆PRL浓度升高的百分比（δ%）表示。在对照组中，PRL分泌对舒必利的反应为639%至2760%。当存在垂体腺瘤或鞍上病变时，PRL对舒必利的反应始终低于481%。另一方面，舒必利后TRH引起的PRL反应在对照组（低于175%）和患者组（低于91%）之间无显著差异。我们得出结论：1）舒必利与TRH联合试验对评估高催乳素血症无用；2）另一方面，舒必利试验能够表明高催乳素血症无法被刺激，并怀疑在这种情况下存在催乳素分泌腺瘤或鞍上肿瘤。
